



Polyclonal Anti-human FLT3-Ligand^{HuXp} Antibody

Specifications

Species	Rabbit
Source	Human cell
Pack Size	100 µg
IsoType	Total IgG
Storage	-20°C

Product Description

Rabbit polyclonal anti-human FLT3-Ligand antibody was raised against recombinant human FLT3-Ligand expressed in human cell (rhFLT3-Ligand^{HuXp}). HumanZyme's human cell expression system has the advantage of tag-free expression and purification, correct folding, accurate tertiary and quaternary structure and authentic post-translational modifications such as glycosylation, phosphorylation, palmitoylation and disulfide bonds. These post-translational modifications are absent in non-human cell expression system and have important implications for cytokine stability, receptor interaction and in vivo efficacy. Total IgG was purified using Protein A affinity chromatography.

Formulation

Lyophilized from 0.2µm filtered solution in PBS+0.02% sodium azide.

Reconstitution

When reconstituted to 1mg/mL, will be 0.007% sodium azide.

Limited Use and Restrictions

Unless otherwise stated in our catalog or other company documentation accompanying the product, products sold by HumanZyme Inc. are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, including resale or use in manufacture, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. For a complete statement of this Limited Use License and its application to drug discovery and diagnostic research please visit www.humanzyme.com

Certificate of Analysis

Polyclonal Anti-human FLT3-Ligand^{HuXp} Antibody

Cat #: HZ-5003


Lot #: I205080003

Background

FLT3-Ligand is a glycoprotein that functions as growth factor controlling the proliferation of early hematopoietic cells and pro B-cells. FLT3-Ligand activity is mediated by binding to the transmembrane glycoprotein FLT3/FLK-2; a class III receptor tyrosine kinase (RTK). The receptor has the extracellular domain made of five Ig-like domains, one transmembrane domain and the cytoplasmic kinase domain. The biological activity is mediated when the receptor is autophosphorylated as result of binding RTK 3 ligand to the extracellular domain. FLT3-Ligand synergizes with several cytokines to stimulate the growth and differentiation of hematopoietic progenitors. Research suggests a role of FLT3 Ligand in cancers such as acute myeloid leukemias. Internal tandem duplications of FLT3 which cause continuous activation of the receptor are present in acute myeloid leukemia patients

Applications

Western Blot - This antibody can be used at 0.5 to 1µg/mL with the appropriate secondary reagents to detect human FLT3-Ligand. The detection limit for rhFLT3-Ligand is approximately 10 ng/lane under reducing and 20 ng/lane under non-reducing conditions.



The Western Blot shows 50ng/lane in reducing and 200ng/lane in non-reducing conditions of FLT3-Ligand from four different expression systems: HuXpTM (lane 2,3), E.coli (lane 4,5), Sfl (lane 6,7), NSO (lane 8,9). Antibody concentration is 1µg/mL.